Drug Type Monoclonal antibody |
Synonyms MSM 735, MSM735 |
Target |
Action inhibitors |
Mechanism CCR7 inhibitors(C-C motif chemokine receptor 7 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hematologic Neoplasms | Preclinical | United States | 30 Jan 2022 | |
| Idiopathic Pulmonary Fibrosis | Preclinical | United States | 30 Jan 2022 | |
| Melanoma | Preclinical | United States | 30 Jan 2022 | |
| Metastatic Solid Tumor | Preclinical | United States | 30 Jan 2022 | |
| Multiple Sclerosis | Preclinical | United States | 30 Jan 2022 | |
| Pancreatic Cancer | Preclinical | United States | 30 Jan 2022 | |
| Stomach Cancer | Preclinical | United States | 30 Jan 2022 |






